padrão voz ativa do verbo (develop - termo depois)

developed_[A-Z]{2,3} (~IN |. ) X (had_VBD |soon_RB |during_IN |.|,|:|;)
	
1. Java: developed_[A-Z]{2,3}\\s(?![\\w-/]*_IN\\s|\\._)((?:[\\w-/]*_[A-Z]{2,3}\\s)*?)(?:had_VBD\\s|soon_RB\\s|during_IN\\s|\\.|,|:|;)
	// Obs: Para cada sentença etiquetada, é necessário remover a barra invertida
		 
2. Perl: developed_[A-Z]{2,3}\s(?![\w-/]*_IN\s|\._)((?:[\w-/\\]*_[A-Z]{2,3}\s)*?)(?:had_VBD\s|soon_RB\s|during_IN\s|\.|,|:|;)
	// \w  Casa letras, dígitos, ou '_'.
	// 1 e 2 são equivalentes
		
Sentences Examples:

HU_NNP was_VBD interrupted_VBN definitely_RB for_IN 12_CD patients_NNS :_: 7_CD underwent_VBD allogeneic_JJ bone_NN marrow_NN transplantation_NN ,_, 1_CD failed_VBD to_TO respond_VB after_IN 2_CD years_NNS of_IN treatment_NN ,_, 1_CD with_IN HbSC_NNP because_IN of_IN a_DT total_JJ Hb_NNP level_NN higher_JJR than_IN 13_CD g\/dL_NNP ,_, 2_CD refused_VBD to_TO pursue_VB the_DT treatment_NN after_IN 1_CD and_CC 2_CD years_NNS ,_, and_CC 1_CD patient_JJ developed_JJ malignancy_NN ._.

Of_IN interest_NN ,_, 4_CD of_IN the_DT children_NNS included_VBN in_IN the_DT registry_NN at_IN younger_JJR than_IN 2_CD years_NNS developed_VBD episodes_NNS of_IN severe_JJ acute_JJ anemia_NN ._.

Six_CD patients_NNS with_IN persistently_RB abnormal_JJ TCD_NNP results_NNS developed_VBD stroke_NN ._.

From_IN the_DT SC_NNP group_NN ,_, 2_CD patients_NNS developed_VBD stroke_NN soon_RB after_IN closure_NN of_IN the_DT trial_NN and_CC started_VBD transfusion_NN -LRB-_-LRB- 1_CD at_IN 2_CD weeks_NNS and_CC another_DT at_IN 10_CD weeks_NNS after_IN the_DT trial_NN -RRB-_-RRB- ._.

In_IN addition_NN to_TO the_DT 12_CD stroke_NN events_NNS in_IN the_DT STOP_NNP trial_NN ,_, 6_CD patients_NNS developed_VBD stroke_NN during_IN the_DT posttrial_JJ follow-up_JJ -LRB-_-LRB- 5_CD from_IN the_DT SC_NNP group_NN and_CC 1_CD from_IN the_DT TX_NNP group_NN -RRB-_-RRB- ._.

From_IN the_DT SC_NNP group_NN ,_, aside_RB from_IN the_DT 2_CD patients_NNS who_WP had_VBD stroke_NN in_IN the_DT immediate_JJ posttrial_JJ period_NN prior_RB to_TO choosing_NN treatment_NN ,_, 1_CD patient_NN who_WP refused_VBD transfusion_NN and_CC 2_CD who_WP started_VBD transfusion_NN during_IN the_DT posttrial_JJ follow-up_JJ developed_JJ stroke_NN ._.

The_DT only_JJ patient_NN from_IN the_DT TX_NNP group_NN who_WP developed_VBD stroke_NN had_VBD discontinued_VBN transfusion_NN after_IN the_DT trial_NN ._.

All_DT 6_CD patients_NNS who_WP developed_VBD stroke_NN during_IN the_DT posttrial_JJ follow-up_NN had_VBD a_DT last_JJ interpretable_JJ TCD_NNP that_WDT was_VBD abnormal_JJ prior_RB to_TO stroke_NN regardless_RB of_IN transfusion_NN status_NN ._.

Treatment_NNP was_VBD also_RB withdrawn_VBN in_IN 5_CD of_IN 6_CD children_NNS who_WP had_VBD developed_VBN hypersplenism_NN ,_, in_IN 3_CD because_IN of_IN a_DT pathological_JJ transcranial_NN Doppler_NNP ,_, and_CC in_IN 2_CD after_IN a_DT stroke_NN ._.

Of_IN the_DT five_CD patients_NNS switched_VBN to_TO hydroxyurea_NN after_IN normalization_NN of_IN their_PRP$ TCD_NNP under_IN transfusion_NN ,_, two_CD developed_JJ velocities_NNS above_IN 200_CD cm\/sec_NN and_CC were_VBD again_RB prescribed_VBN regular_JJ exchange_NN blood_NN transfusions_NNS ._.